Alchemab aims to revolutionise drug discovery with a novel alternative to the classic “choose a target” approach.
Alchemab specifically looks to identify shared antibodies from people who have shown resilience to disease – the unexpectedly well. The company then uses its proprietary technology to identify which targets these antibodies are binding to, and what diseases these targets are associated with.
Optimum Strategic Communications’ Richard Staines caught up with Alchemab’s CEO, Young Kwon, to find out more.
","author_name":"Optimum Strategic Communications"}